DVC LLC

DynPort Vaccine Company LLC, a CSC company, manages product development programs for U.S. and international government agencies, and provides consulting services to biotechnology and pharmaceutical companies. More on what we do.

DynPort releases rBV A/B trial results

We released Phase 2 clinical trial results for our botulinum neurotoxin vaccine candidate; rBV A/B was safe and well-tolerated among trial volunteers.

ASM Biodefense
February 26-29, 2012
Visit us in booth 38 at the ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC, or contact us to arrange a private meeting.

Joint CBRN Conference and Exhibition

March 12-14, 2012

Join government, military and industry leaders in Baltimore, MD for the 2012 Joint Chemical, Biological, Radiological, and Nuclear (CBRN) Conference and Exhibition.

Our newsletter isn't about us
Check out our February/March edition for hot industry topics, biotech funding, abstract deadlines, news and events. Subscribe, and never miss an issue.

New influenza vaccine publications
View new research on cell-culture derived influenza vaccines in the journals Clinical Infectious Diseases and Vaccine.

DynPort named to Best Places to Work
DVC took top honors in the large business category for our family-friendly work environment and innovative benefits.

Why choose DVC?
You can't afford to pay for a learning curve. With DVC, you don't have to. Learn more about how we can help you.